HRP20201316T1 - Novi modulatori receptora sfingozin-fosfata - Google Patents

Novi modulatori receptora sfingozin-fosfata Download PDF

Info

Publication number
HRP20201316T1
HRP20201316T1 HRP20201316TT HRP20201316T HRP20201316T1 HR P20201316 T1 HRP20201316 T1 HR P20201316T1 HR P20201316T T HRP20201316T T HR P20201316TT HR P20201316 T HRP20201316 T HR P20201316T HR P20201316 T1 HRP20201316 T1 HR P20201316T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
compound
pharmaceutical preparation
stereoisomer
solvate
Prior art date
Application number
HRP20201316TT
Other languages
English (en)
Croatian (hr)
Inventor
Edward Roberts
Hugh Rosen
Steven Brown
Miguel A. Guerrero
Xuemei Peng
Ramulu Poddutoori
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15158887.8A external-priority patent/EP2913326B1/en
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of HRP20201316T1 publication Critical patent/HRP20201316T1/hr

Links

HRP20201316TT 2008-05-14 2020-08-24 Novi modulatori receptora sfingozin-fosfata HRP20201316T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12760308P 2008-05-14 2008-05-14
EP15158887.8A EP2913326B1 (en) 2008-05-14 2009-05-14 Novel modulators of sphingosine phosphate receptors

Publications (1)

Publication Number Publication Date
HRP20201316T1 true HRP20201316T1 (hr) 2020-11-27

Family

ID=43426295

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201316TT HRP20201316T1 (hr) 2008-05-14 2020-08-24 Novi modulatori receptora sfingozin-fosfata

Country Status (12)

Country Link
KR (2) KR101582910B1 (he)
CN (1) CN102118972B (he)
BR (1) BRPI0912545B1 (he)
CA (1) CA2723904C (he)
DK (1) DK2913326T3 (he)
HR (1) HRP20201316T1 (he)
HU (1) HUE050411T2 (he)
IL (1) IL209306A (he)
LT (1) LT2913326T (he)
MX (1) MX2010012461A (he)
SI (1) SI2913326T1 (he)
ZA (1) ZA201007804B (he)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025984T2 (hu) 2008-05-14 2016-05-30 Scripps Research Inst Szfingozin foszfát receptor új modulátorai
WO2015196258A1 (en) * 2014-06-26 2015-12-30 Monash University Enzyme interacting agents
EP3470400A1 (en) 2016-06-14 2019-04-17 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of ozanimod, crystal form of hydrochloride thereof, and preparation method therefor
CN109563059A (zh) 2016-08-19 2019-04-02 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
CN109640982A (zh) 2016-09-14 2019-04-16 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
CN108137516A (zh) 2016-09-14 2018-06-08 杭州领业医药科技有限公司 奥扎莫德的晶型、其制备方法及药物组合物
CN106749213B (zh) * 2016-11-25 2019-07-02 济南大学 一种具有1,2,4-恶二唑结构的吲哚衍生物及制备方法和在制备抗菌药物中的应用
WO2019042219A1 (zh) 2017-08-31 2019-03-07 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
CN107827837B (zh) * 2017-11-21 2021-09-24 苏州朗科生物技术股份有限公司 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4516430B2 (ja) * 2002-12-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション 1−(アミノ)インダン並びに(1,2−ジヒドロ−3−アミノ)−ベンゾフラン、ベンゾチオフェン及びインドール
CA2648303C (en) * 2006-04-03 2014-07-15 Astellas Pharma Inc. 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists

Also Published As

Publication number Publication date
BRPI0912545B1 (pt) 2022-02-01
LT2913326T (lt) 2020-09-10
CN102118972B (zh) 2015-06-10
IL209306A0 (en) 2011-01-31
BRPI0912545A2 (pt) 2021-04-13
CA2723904C (en) 2017-03-14
KR20110010777A (ko) 2011-02-07
ZA201007804B (en) 2012-01-25
KR20150064245A (ko) 2015-06-10
MX2010012461A (es) 2013-07-02
SI2913326T1 (sl) 2020-11-30
IL209306A (he) 2017-02-28
CN102118972A (zh) 2011-07-06
CA2723904A1 (en) 2009-12-17
DK2913326T3 (da) 2020-08-17
HUE050411T2 (hu) 2020-12-28
KR101582910B1 (ko) 2016-01-08

Similar Documents

Publication Publication Date Title
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
HRP20150982T1 (hr) Novi modulatori sfingozin fosfat receptora
HRP20160189T1 (hr) Liječenje crohnove bolesti lakvinimodom
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
HRP20120323T4 (hr) Spoj diaril-hidantoina
AU2018278332A1 (en) Methods and compositions for treating excessive sleepiness
HRP20151357T1 (hr) Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa
JP2009525343A5 (he)
JP2013199505A5 (he)
JP2011068653A5 (he)
JP2018513852A5 (he)
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
JP2015529234A5 (he)
JP2011173928A5 (he)
JP2012255026A5 (he)
JP2015522630A5 (he)
JP2010527347A5 (he)
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
KR20160112012A (ko) 질내 투여용 속용성 정제 조성물
JP2013516493A5 (he)
MX342062B (es) Composicion farmaceutica para administracion oral.
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2021505575A5 (he)